News & Updates

Articles

Cablivi Patient Support

Help your aTTP/iTTP* patients transition from hospital to home with CABLIVI.

PRESS RELEASE: Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan, and CAMBRIDGE, Massachusetts, November 9, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.1,2

MAYARI Study

Living with iTTP? Worried about relapse? If you have an acute episode the MAYARI Study may interest you.

Clinical Trials

Have questions? We’ve got answers. Read more.

Patients and Families Overview

What is delirium? The word “delirium” is used to describe a severe state of confusion. Read more.

USTMA Patient Resources

Learn more about USTMA’s free patient resources.

Thrombocytopenia Copay Assistance Program

TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists are administered on a calendar-year basis. At the end of each calendar year, waitlist applications expire. Patients still seeking assistance must join waitlists for the subsequent calendar year.

PRESS RELEASE: Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

On Sunday, June 25, 2023, Takeda announced, interim data from our pivotal, Phase 3 clinical trial on TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP).

“You May Have This Disorder—And Not Even Know It”, Black Health Matters.com

Black Health Matters highlighted our Beloved Reeshemah Wynn.

Reeshemah Wynn went to the emergency room with what she thought was the flu, but she was later diagnosed with a rare blood disorder called aTTP.

“Health Following Recovery from Immune Thrombotic Thrombocytopenic Purpura: The Patient’s Perspective”, Blood Advances

Blood Adv 2023; 7 (9): 1813–1822. doi: https://doi.org/10.1182/bloodadvances.2022008342
Authors: Rachel A. Kelley, Marshall K. Cheney, Clare M. Martin, Spero Cataland, Lauren B. Quick, San Keller, Sara K. Vesely, Amanda J. Llaneza, Mohamad O. Khawandanah, Janna M. Journeycake, Julie A. Panepinto, Deirdra R. Terrell

“Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) – cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom”, Hematology

Hematology, 26:1, 465-472, DOI: https://doi.org/10.1080/16078454.2021.1945236

Authors: Steve Holmes, Lauren Podger, Catherine Bottomley, Ewelina Rzepa, Karen M. A. Bailey & Fleur Chandler (2021) Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) – cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom

Orpha.net, Portal for Rare Diseases

Learn more about Thrombotic thrombocytopenic purpura at Oprha.net, The portal for rare diseases and orphan drugs.


Videos